731 related articles for article (PubMed ID: 26552009)
1. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2.
Kim KH; Kim W; Howard TP; Vazquez F; Tsherniak A; Wu JN; Wang W; Haswell JR; Walensky LD; Hahn WC; Orkin SH; Roberts CW
Nat Med; 2015 Dec; 21(12):1491-6. PubMed ID: 26552009
[TBL] [Abstract][Full Text] [Related]
2. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL
Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303
[TBL] [Abstract][Full Text] [Related]
3. SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells.
Wu S; Fatkhutdinov N; Fukumoto T; Bitler BG; Park PH; Kossenkov AV; Trizzino M; Tang HY; Zhang L; Gardini A; Speicher DW; Zhang R
Nat Commun; 2018 Oct; 9(1):4116. PubMed ID: 30297712
[TBL] [Abstract][Full Text] [Related]
4. Potential of enhancer of zeste homolog 2 inhibitors for the treatment of SWI/SNF mutant cancers and tumor microenvironment modulation.
Pyziak K; Sroka-Porada A; Rzymski T; Dulak J; Łoboda A
Drug Dev Res; 2021 Sep; 82(6):730-753. PubMed ID: 33565092
[TBL] [Abstract][Full Text] [Related]
5. Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2:
Chan-Penebre E; Armstrong K; Drew A; Grassian AR; Feldman I; Knutson SK; Kuplast-Barr K; Roche M; Campbell J; Ho P; Copeland RA; Chesworth R; Smith JJ; Keilhack H; Ribich SA
Mol Cancer Ther; 2017 May; 16(5):850-860. PubMed ID: 28292935
[TBL] [Abstract][Full Text] [Related]
6. The spectrum of SWI/SNF mutations, ubiquitous in human cancers.
Shain AH; Pollack JR
PLoS One; 2013; 8(1):e55119. PubMed ID: 23355908
[TBL] [Abstract][Full Text] [Related]
7. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.
Kawano S; Grassian AR; Tsuda M; Knutson SK; Warholic NM; Kuznetsov G; Xu S; Xiao Y; Pollock RM; Smith JS; Kuntz KK; Ribich S; Minoshima Y; Matsui J; Copeland RA; Tanaka S; Keilhack H
PLoS One; 2016; 11(7):e0158888. PubMed ID: 27391784
[TBL] [Abstract][Full Text] [Related]
9. PRC2 and SWI/SNF Chromatin Remodeling Complexes in Health and Disease.
Kadoch C; Copeland RA; Keilhack H
Biochemistry; 2016 Mar; 55(11):1600-14. PubMed ID: 26836503
[TBL] [Abstract][Full Text] [Related]
10. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.
Bitler BG; Aird KM; Garipov A; Li H; Amatangelo M; Kossenkov AV; Schultz DC; Liu Q; Shih IeM; Conejo-Garcia JR; Speicher DW; Zhang R
Nat Med; 2015 Mar; 21(3):231-8. PubMed ID: 25686104
[TBL] [Abstract][Full Text] [Related]
11. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
[TBL] [Abstract][Full Text] [Related]
12. Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.
Baker T; Nerle S; Pritchard J; Zhao B; Rivera VM; Garner A; Gonzalvez F
Oncotarget; 2015 Oct; 6(32):32646-55. PubMed ID: 26360609
[TBL] [Abstract][Full Text] [Related]
13. Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer.
Shain AH; Giacomini CP; Matsukuma K; Karikari CA; Bashyam MD; Hidalgo M; Maitra A; Pollack JR
Proc Natl Acad Sci U S A; 2012 Jan; 109(5):E252-9. PubMed ID: 22233809
[TBL] [Abstract][Full Text] [Related]
14. ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?
Garczyk S; Schneider U; Lurje I; Becker K; Vögeli TA; Gaisa NT; Knüchel R
PLoS One; 2018; 13(8):e0202965. PubMed ID: 30138427
[TBL] [Abstract][Full Text] [Related]
15. Composition and Function of Mutant Swi/Snf Complexes.
Dutta A; Sardiu M; Gogol M; Gilmore J; Zhang D; Florens L; Abmayr SM; Washburn MP; Workman JL
Cell Rep; 2017 Feb; 18(9):2124-2134. PubMed ID: 28249159
[TBL] [Abstract][Full Text] [Related]
16. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer.
Soldi R; Ghosh Halder T; Weston A; Thode T; Drenner K; Lewis R; Kaadige MR; Srivastava S; Daniel Ampanattu S; Rodriguez Del Villar R; Lang J; Vankayalapati H; Weissman B; Trent JM; Hendricks WPD; Sharma S
PLoS One; 2020; 15(7):e0235705. PubMed ID: 32649682
[TBL] [Abstract][Full Text] [Related]
17. BAFfling pathologies: Alterations of BAF complexes in cancer.
Arnaud O; Le Loarer F; Tirode F
Cancer Lett; 2018 Apr; 419():266-279. PubMed ID: 29374542
[TBL] [Abstract][Full Text] [Related]
18. NSD1 mediates antagonism between SWI/SNF and polycomb complexes and is required for transcriptional activation upon EZH2 inhibition.
Drosos Y; Myers JA; Xu B; Mathias KM; Beane EC; Radko-Juettner S; Mobley RJ; Larsen ME; Piccioni F; Ma X; Low J; Hansen BS; Peters ST; Bhanu NV; Dhanda SK; Chen T; Upadhyaya SA; Pruett-Miller SM; Root DE; Garcia BA; Partridge JF; Roberts CWM
Mol Cell; 2022 Jul; 82(13):2472-2489.e8. PubMed ID: 35537449
[TBL] [Abstract][Full Text] [Related]
19. Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
Xu B; Konze KD; Jin J; Wang GG
Exp Hematol; 2015 Aug; 43(8):698-712. PubMed ID: 26027790
[TBL] [Abstract][Full Text] [Related]
20. The SWI/SNF Complex: A Frequently Mutated Chromatin Remodeling Complex in Cancer.
Nguyen VT; Tessema M; Weissman BE
Cancer Treat Res; 2023; 190():211-244. PubMed ID: 38113003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
